Compare Aurobindo Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs NOVARTIS - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA NOVARTIS AUROBINDO PHARMA/
NOVARTIS
 
P/E (TTM) x 10.7 470.5 2.3% View Chart
P/BV x 2.3 27.3 8.5% View Chart
Dividend Yield % 0.5 1.7 32.2%  

Financials

 AUROBINDO PHARMA   NOVARTIS
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
NOVARTIS
Mar-18
AUROBINDO PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs809758 106.7%   
Low Rs504579 87.0%   
Sales per share (Unadj.) Rs281.1228.4 123.1%  
Earnings per share (Unadj.) Rs41.431.7 130.3%  
Cash flow per share (Unadj.) Rs50.932.8 155.3%  
Dividends per share (Unadj.) Rs2.5010.00 25.0%  
Dividend yield (eoy) %0.41.5 25.5%  
Book value per share (Unadj.) Rs199.4297.1 67.1%  
Shares outstanding (eoy) m585.8824.69 2,372.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.32.9 79.8%   
Avg P/E ratio x15.921.1 75.4%  
P/CF ratio (eoy) x12.920.4 63.2%  
Price / Book Value ratio x3.32.2 146.4%  
Dividend payout %6.031.5 19.2%   
Avg Mkt Cap Rs m384,63016,505 2,330.3%   
No. of employees `00017.30.7 2,594.6%   
Total wages/salary Rs m21,3081,445 1,474.3%   
Avg. sales/employee Rs Th9,500.78,441.3 112.5%   
Avg. wages/employee Rs Th1,229.42,163.6 56.8%   
Avg. net profit/employee Rs Th1,397.91,173.1 119.2%   
INCOME DATA
Net Sales Rs m164,6665,639 2,920.2%  
Other income Rs m1,0201,718 59.3%   
Total revenues Rs m165,6867,357 2,252.1%   
Gross profit Rs m37,718-63 -60,348.0%  
Depreciation Rs m5,58025 22,054.2%   
Interest Rs m77755 1,405.4%   
Profit before tax Rs m32,3801,575 2,055.6%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,183792 1,033.7%   
Profit after tax Rs m24,229784 3,092.0%  
Gross profit margin %22.9-1.1 -2,066.6%  
Effective tax rate %25.350.3 50.3%   
Net profit margin %14.713.9 105.9%  
BALANCE SHEET DATA
Current assets Rs m121,8789,522 1,280.0%   
Current liabilities Rs m86,8063,296 2,633.7%   
Net working cap to sales %21.3110.4 19.3%  
Current ratio x1.42.9 48.6%  
Inventory Days Days13037 354.7%  
Debtors Days Days6828 240.5%  
Net fixed assets Rs m81,03746 176,167.8%   
Share capital Rs m586123 474.8%   
"Free" reserves Rs m116,2187,213 1,611.2%   
Net worth Rs m116,8047,336 1,592.1%   
Long term debt Rs m4,5120-   
Total assets Rs m211,05211,105 1,900.5%  
Interest coverage x42.729.5 144.7%   
Debt to equity ratio x00-  
Sales to assets ratio x0.80.5 153.7%   
Return on assets %11.87.6 156.8%  
Return on equity %20.710.7 194.2%  
Return on capital %27.422.2 123.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72761 133,213.2%   
Fx outflow Rs m34,7003,630 955.9%   
Net fx Rs m46,027-3,570 -1,289.4%   
CASH FLOW
From Operations Rs m19,5481,610 1,214.2%  
From Investments Rs m-19,570687 -2,848.5%  
From Financial Activity Rs m8,642-2,677 -322.9%  
Net Cashflow Rs m8,922-380 -2,350.4%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 8.0 2.0 397.5%  
FIIs % 27.7 1.6 1,731.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 21.5 47.4%  
Shareholders   69,601 41,647 167.1%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   FULFORD INDIA  VENUS REMEDIES  IPCA LABS  WOCKHARDT  SUVEN LIFESCIENCES  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 93 Points Higher; Oil & Gas and Realty Stocks Witness Buying(Closing)

Indian share markets traded on a volatile note throughout the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the oil & gas sector.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Oct 16, 2019 03:37 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS